NeuroMetrix Inc
NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing and sale of medical devices. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; and Quell, a wearable device for symptomatic relief and management of chronic pain. The company offers its products to managed endoc… Read more
Market Cap & Net Worth: NeuroMetrix Inc (NURO)
NeuroMetrix Inc (NASDAQ:NURO) has a market capitalization of $9.43 Million ($9.43 Million) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #30065 globally and #9920 in its home market, demonstrating a 4.69% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying NeuroMetrix Inc's stock price $4.58 by its total outstanding shares 2059690 (2.06 Million).
NeuroMetrix Inc Market Cap History: 2015 to 2025
NeuroMetrix Inc's market capitalization history from 2015 to 2025. Data shows change from $2.61 Billion to $9.43 Million (-47.59% CAGR).
Index Memberships
NeuroMetrix Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.00% | #778 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #2476 of 3165 |
Weight: NeuroMetrix Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
NeuroMetrix Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how NeuroMetrix Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.70x
NeuroMetrix Inc's market cap is 2.70 times its annual revenue
0.67x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $2.61 Billion | $7.30 Million | -$9.19 Million | 357.55x | N/A |
| 2016 | $973.62 Million | $12.03 Million | -$14.91 Million | 80.95x | N/A |
| 2017 | $284.90 Million | $17.09 Million | -$12.86 Million | 16.67x | N/A |
| 2018 | $125.23 Million | $16.09 Million | $23.61K | 7.78x | 5305.20x |
| 2019 | $70.85 Million | $9.27 Million | -$3.65 Million | 7.64x | N/A |
| 2020 | $52.07 Million | $7.38 Million | -$2.00 Million | 7.06x | N/A |
| 2021 | $82.72 Million | $8.25 Million | -$2.21 Million | 10.02x | N/A |
| 2022 | $24.55 Million | $8.26 Million | -$4.37 Million | 2.97x | N/A |
| 2023 | $7.41 Million | $5.90 Million | -$6.53 Million | 1.26x | N/A |
| 2024 | $8.18 Million | $3.03 Million | -$7.81 Million | 2.70x | N/A |
Competitor Companies of NURO by Market Capitalization
Companies near NeuroMetrix Inc in the global market cap rankings as of March 19, 2026.
Key companies related to NeuroMetrix Inc by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #78 globally with a market cap of $191.37 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #154 globally with a market cap of $121.03 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #168 globally with a market cap of $113.17 Billion USD.
- Boston Scientific Corp (NYSE:BSX): Ranked #185 globally with a market cap of $105.26 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #78 | Abbott Laboratories | NYSE:ABT | $191.37 Billion | $110.71 |
| #154 | Stryker Corporation | NYSE:SYK | $121.03 Billion | $349.11 |
| #168 | Medtronic PLC | NYSE:MDT | $113.17 Billion | $88.44 |
| #185 | Boston Scientific Corp | NYSE:BSX | $105.26 Billion | $71.20 |
NeuroMetrix Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, NeuroMetrix Inc's market cap moved from $2.61 Billion to $ 9.43 Million, with a yearly change of -47.59%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $9.43 Million | +15.37% |
| 2024 | $8.18 Million | +10.28% |
| 2023 | $7.41 Million | -69.80% |
| 2022 | $24.55 Million | -70.32% |
| 2021 | $82.72 Million | +58.86% |
| 2020 | $52.07 Million | -26.51% |
| 2019 | $70.85 Million | -43.42% |
| 2018 | $125.23 Million | -56.04% |
| 2017 | $284.90 Million | -70.74% |
| 2016 | $973.62 Million | -62.70% |
| 2015 | $2.61 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of NeuroMetrix Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $9.43 Million USD |
| MoneyControl | $9.43 Million USD |
| MarketWatch | $9.43 Million USD |
| marketcap.company | $9.43 Million USD |
| Reuters | $9.43 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.